Press Release

Anti-Fungal Drugs Market to Grow with a CAGR of 3.18% through 2028

Increasing number of antifungal drugs as over the counter and rising consumption of antifungal drugs in developing regions is expected to drive the Global Anti-Fungal Drugs Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “Anti-Fungal Drugs Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Anti-Fungal Drugs Market stood at USD 10.04 billion in 2022 and is anticipated to grow with a CAGR of 3.18% in the forecast period, 2024-2028. The antifungal drugs market is witnessing significant expansion due to the growing prevalence of various fungal infections, including fungal nail infections, ringworm, and more.

Moreover, the increasing demand for antifungal drugs as over the counter (OTC) medications, the rising demand for generic antifungal drugs, the escalating incidence of nosocomial infections worldwide, and the continuous drug innovations such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, among others, will contribute to the surge in antifungal drug demand.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Anti-Fungal Drugs Market.”


Market drivers, such as the increasing prevalence of fungal infections, present significant growth opportunities for vendors. However, market participants will face challenges due to factors like the rise of multidrug-resistant fungal pathogens. To capitalize on these opportunities, market vendors should prioritize growth prospects in fast-growing segments while maintaining their positions in slow-growing segments.

Driving demand in the global antifungal drugs market is the growing awareness of fungal infections and the rising instances of such infections due to unhygienic environments in densely populated cities. The most prevalent systemic fungal infection, systemic candidiasis, is expected to drive growth in the coming years. The availability of various antifungal drugs and the popularity of over-the-counter antifungal drugs for dermal infections have positively impacted the market. Antifungal drugs play a crucial role in inhibiting fungal cell wall development, disrupting cell membranes, and preventing cell proliferation. The market for antifungal therapies includes powders, drugs, pastes, and ointments. Azoles antifungal drugs currently hold a dominant share in the market, driven by increasing awareness.

Additionally, the rising demand for antifungal powder contributes to the market's revenue growth. Antifungal powder not only cures fungal infections but also reduces itching, inhibits recurrence, and provides relaxing maintenance therapy. These drugs help prevent and treat fungal skin infections caused by sweat and moisture. Therefore, powder-form drugs are used to treat itching, irritation, rashes, and swelling in various body parts containing Clotrimazole, which effectively destroys fungi and drives revenue growth. In May 2022, Bayer's Consumer Health division launched the new and improved Canesten anti-fungal treatment solution in India, available in powder and cream forms. These products possess anti-fungal characteristics that aid in the prevention and treatment of skin infections.


Other factors contributing to market growth include favorable government initiatives, corporate funds, and growing healthcare budgets in developing economies. Technological advancements in diagnostic tests and devices have also contributed to more accurate treatment, further fueling market growth. However, the continued preference for conventional drugs and the high cost and side effects of antifungal drugs poses challenges to their swift adoption. Additionally, the diminishing efficacy of drugs due to increasing fungal resistance is another market challenge to address.


The Global Anti-Fungal Drugs Market is segmented into drug class, indication, infection type, route of administration, end user, distribution channel, regional distribution, and company.


Based on drug class, the azoles segment is anticipated to witness significant growth during the forecast period. The azole group of compounds serves as antifungal agents that have greatly expanded therapeutic options for the treatment of systemic fungal infections. Research in the field of fungal drugs is rapidly advancing, thanks to the development of new antifungal drugs utilizing the azole group. Synthetic azoles and semi-synthetic compounds are extensively utilized for fungal infections, contributing to the projected substantial growth of this segment over the analysis period. Azole group drugs are employed for the treatment of various fungal infections, including thrush, yeast infections, candidiasis, aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, systemic mycosis, and seborrheic dermatitis. The azole antifungal group encompasses two categories: triazoles (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) and imidazoles (ketoconazole).

Triazoles find broad applications in the treatment of both external fungal infections and systemic infections. The azole group offers a wide spectrum of activity and improved safety standards. These medications exhibit fewer side effects, minimal drug interactions, and enhanced absorption and distribution properties. These advantages of azoles have contributed to their superiority over other components, further propelling the growth of this segment. Additionally, the development and innovation of such potential drugs enhance the competitiveness of the pharmaceutical market. In October 2021, Intas Pharmaceuticals Limited launched an innovative antifungal drug, Super Bioavailable Itraconazole-SB 100 mg, marketed as Itaspor-SB Forte/Subawin. Furthermore, in June 2021, Cadila Pharmaceuticals introduced a new triazole antifungal drug, Posaconazole, which demonstrates efficacy against a wide range of invasive fungal diseases. The drug has also been recommended as a second-line treatment for Mucormycosis. Such advancements are expected to drive the growth of this segment during the forecast period.

Based on region, North America segment is expected to grow during the forecast period.  North America is anticipated to hold a significant share in the market analysis and is poised to maintain its strong position throughout the analysis period. This growth can be attributed to various factors, including the increasing prevalence of fungal infections among the target population and the heightened company activities for product development across the region. Among the countries in the region, the United States, along with Canada and Mexico, stands out as one of the most economically developed. However, the country has faced challenges in dealing with fungal infections, as highlighted by the Centers for Disease Control and Prevention (CDC) data updated in June 2022. According to the CDC, Candida has emerged as a common cause of bloodstream infections in the United States, with the presence of drug-resistant strains posing additional concerns. Consequently, there is a growing demand for anti-fungal drugs in the United States. Furthermore, Canada has witnessed recent outbreaks of fungal infections, further increasing the need for anti-fungal drugs. For example, in September 2022, Quebec's health ministry reported the first-ever outbreak of the potentially deadly fungus "Candida auris" at Pierre Boucher Hospital in Longueuil. Candida auris, a type of yeast that can cause severe illness, presents a greater risk to admitted patients and caregivers in healthcare settings. These instances, coupled with the burden of infections, have underscored the necessity for anti-fungal drugs and are expected to fuel market growth in the region.

Moreover, market players' product approvals and launches are intensifying competition. Notably, in June 2021, Scynexis announced the FDA approval of Brexafemme for the treatment of vaginal yeast infections. Additionally, in January 2021, Sandoz Canada Inc. introduced PrSandoz Posaconazole, becoming the first company to offer posaconazole generics in the Canadian market. Sandoz Posaconazole is utilized for treating Aspergillus fungal infections and preventing fungal infections caused by Aspergillus and Candida, particularly in oncology patients with a history of stem cell transplant. These company activities, along with the burden of fungal infections, are expected to drive market growth in the region throughout the forecast period.


Major companies operating in Global Anti-Fungal Drugs Market are:

  • Abbott Laboratories Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • GSK plc
  • Glenmark Pharmaceuticals Limited
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Apex Laboratories Pvt. Ltd.


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The increasing prevalence of fungal and nosocomial infections is a key factor that contributes to a positive market outlook. Antifungal drugs demonstrate efficacy against both systemic and superficial infections acquired from exposure to contaminated surfaces in hospitals or humid conditions. Furthermore, the convenient availability of over the counter (OTC) drugs in urban and rural areas propels market growth. As health consciousness rises among the masses, consumers increasingly choose OTC therapeutics for timely treatment of minor infections. Moreover, product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for invasive fungal infection treatment, serve as growth-inducing factors. Pharmaceutical manufacturers invest extensively in research and development (R&D) of novel therapeutics in the form of sprays, creams, tablets, and injections with enhanced efficacy. Additionally, significant growth in the pharmaceutical industry, coupled with favorable government policies promoting public health, is anticipated to drive market growth.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Anti-Fungal Drugs Market Segmented By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others), By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection), By Route of Administration (Topical, Oral, Parenteral, Others), By End User (Homecare, Hospitals, Clinics, Others), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Anti-Fungal Drugs Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Anti-Fungal Drugs Market.



Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]


Relevant News